Clinical Trial Update: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for STI-6129 in relapsed or refractory systemic AL amyloidosis (Phase 1/Phase 2) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• STI-6129

Snippet

Sponsor: Sorrento Therapeutics, Inc. | Conditions: Light Chain (AL) Amyloidosis | Phase 1, Phase 2 | Status: UNKNOWN